USE OF EPOPHILONES IN THE TREATMENT OF BRAIN DISEASES ASSOCIATED WITH PROLIFERATIVE PROCESSES

Compound 1
Plasma and Brain Concentration after iv Application

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Concentration (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2.0</td>
</tr>
<tr>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>1.5</td>
<td>0.5</td>
</tr>
<tr>
<td>2.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

Compound 1: 4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-7-(1-propyl)-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione

Abstract: This invention provides the use of an Epophilone, which shows an average distribution coefficient between plasma and brain of 0.3 to 1.5 in the mouse intravenous bolus injection assay, for the preparation of a medicament for the treatment of a brain disease associated with proliferative processes.
Declaration under Rule 4.17:
— as to the identity of the inventor (Rule 4.17(i)) for all designations

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
Use of Epothilones in the Treatment of Brain Diseases
Associated with Proliferative Processes

Field of the Invention

The present invention relates to the use of Epothilones in the treatment of brain diseases associated with proliferative processes, especially primary or secondary brain tumors, multiple sclerosis, and Alzheimer’s disease.

Background of the Invention

The possibilities of medicamentous treatment of brain diseases are strongly limited by the existence of the so-called blood-brain-barrier (BBB). While the BBB serves as a protective mechanism for preventing exogenous substances to enter the brain tissue, unfortunately, it also prevents the entry of drugs administered by a conventional mode (orally, parenterally, etc.) (A. Maelicke, Nachr. Chem Tech. Lab. 1989, 37, 32-34).

An important class of brain diseases which are difficult to treat with medicaments for the above-cited reason are diseases associated with proliferative processes such as brain tumors, multiple sclerosis, or Alzheimer’s disease. Various studies regarding these diseases, especially cancer, have provided some insights into the efficiency of drug targeting to the brain (W. Shapiro, J. Shapiro, Semin. Oncol. 1986, 13, 56-69; M. Donelli et al., Cancer Chemother. Pharmacol. 1992, 30, 251-260). As a rule of thumb, a drug reaches higher concentrations in the brain the lower its molecular mass and the higher its lipophilicity is (C. Unger et al., Klin. Wochenschr. 1985, 63, 565-571). Nevertheless, it has been found in recent years, that for at least some compounds (M. Fromm, Int. J. Clin. Pharmacol. Ther. 2000, 38, 69-74) active exclusion mechanisms exist within the BBB, so that drug uptake by brain tissue cannot be simply calculated from physical or chemical data but has to be determined experimentally.
Some experimental methods have been developed to overcome the restrictions of drug uptake by brain tissue caused by the BBB; e.g., direct intrathecal drug application, use of lipid-soluble carriers, or disruption of the BBB by application of high doses of mannitol or other compounds (E. Galanis et al., *Curr. Opin. Neurol.* **2000**, *13*, 619-625; H. Lahrmann et al., *J. Neurol. Neurochir. Psychiatr.* **2001**, *2*, 16-20). These methods are, however, associated with considerable disadvantages and/or undesirable side effects. Most of them can be considered to be in an experimental stage, i.e., they cannot be considered as standard therapies.

As a result of the previous work it can be stated that most cytostatic agents (which is the most important class of drugs for the treatment of diseases associated with proliferative processes) do not reach the same concentration in brain liquor as in blood plasma when applied systemically. For example, it has lately been found that maximum liquor concentrations of 20-30% of the plasma concentrations may be reached when using nitrosoureas, which are considered to be the best BBB penetrating type of cytostatic agents (*Therapiekonzepte Onkologie*; Seeberger, S, Schütte, J. (Eds.), 3rd edition, Springer, Berlin 1998). Nitrosoureas and a combination of nitrosoureas with procarbazine and vincristine (PCV therapy) are considered to be standard chemotherapeutic agents for the treatment of brain cancer (H. Lahrmann et al., *J. Neurol. Neurochir. Psychiatr.* **2001**, *2*, 16-20; E. Galanis et al., *Curr. Opin. Neurol.* **2000**, *13*, 619-625).

Cytostatic agents can be distinguished according to the mechanism of their pharmacological activity. The most important classes of cytostatic compounds are antimetabolites (e.g. fluorouracil, cytarabine, mercaptopurine), antimitotic agents (e.g. colchicine, paclitaxel, podophyllotoxine, *Vinca*-alkaloids), alkylating agents (e.g. cisplatine, nitrosoureas, nitrogen mustards), antibiotics (e.g. bleomycin), and agents in respect of which the mechanism of their therapeutic effectiveness is not known (e.g. asparaginase).
Although alkylating agents have been found to be useful for cancer treatment, it is an enormous disadvantage of these compounds that their pharmacological mechanism bears a strong carcinogenic potential itself.

In particular nitroso compounds (nitrosoureas and nitroso amines), which were discussed above to be efficient drugs for the treatment of the brain, show these effects: 57 of 60 nitrosoureas (95 %) tested on carcinogenic activity were active (CD Römp Chemie Lexikon – Version 1.0, Stuttgart/New York: Georg Thieme Verlag 1995). It would thus be desirable to provide compounds for the efficient treatment of brain diseases associated with proliferative processes which have similar or better BBB-penetrating properties as nitrosoureas, but without their carcinogenic potential.

Within the group of antimitotic agents, Paclitaxel (Taxol®) is the best-known member and one of the best-selling anticancer medicaments in the present time. Unfortunately, paclitaxel has only low ability to penetrate the BBB (M. Glantz et al., J. Natl. Cancer Inst. 1995, 87, 1077-1081) and is thus not considered to be useful for the treatment of brain diseases via conventional administration routes. Other antimitotic agents, which block the mitotic spindle of a proliferating cell by binding to the spindle-peptide tubulin, and thus cause apoptosis, have been found to be powerful anticancer agents (K.-H. Altmann, Curr. Opin. Chem. Biol. 2001, 5, 424-431), in respect of which less carcinogenic side effects have been reported than in the case of the alkylating agents discussed above. Epothilones also belong to this group of drugs.

The natural products Epothilone A and B as well as some of their synthetic derivatives have recently found interest in connection with the treatment of cancer, and a lot of work has been done on their synthesis (K. Nicolaou et al., Angew. Chem. 1998, 110, 2120-2153) and the synthesis of modified structures.

WO 00/66589 deals with the synthesis and pharmaceutical use of Epothilone derivatives having an alkenyl, alkynyl, or an cyclic ether containing substituent at the 6-position of the macrocyclic ring.

WO 00/49021 discloses Epothilone derivatives with a halogen substituent in 16-position and their synthesis.

WO 00/71521 discloses a method for the synthesis of olefinic Epothilones.

WO 98/25929 deals with the manufacture of libraries of Epothilone analogs.

WO 99/43320 mentions, in a very general manner, the use of Epothilones for the treatment of cancer. The disclosure focuses on the development of application conditions for the particular compound Epothilone B for the treatment of a wide range of cancer varieties. There is no mention in this document of the difficulties of treating brain diseases associated with proliferative processes as discussed above, or of any specific advantages of using Epothilones in this regard.

It has now unexpectedly been found that certain Epothilones show a particularly good ability to penetrate the BBB compared to other cytostatic agents (antimitotic agents and others), and thus, are particularly useful for the manufacture of medicaments for the treatment of brain diseases associated with proliferative processes. Due to their pharmacological mechanism of action, these compounds can also be used for the treatment of diseases other than cancer, which are associated with proliferative activity.

Summary of the Invention

Accordingly, the present invention relates to the use of Epothilones for the treatment of brain diseases associated with proliferative processes, or for the preparation of a
medicament for the treatment of brain diseases associated with proliferative processes. It also relates to methods of treating brain diseases associated with proliferative processes by oral, rectal, local, or parenteral, preferably inhalational, intravenous, or intraperitoneal, most preferably intravenous administration of an Epothilone.

For the purposes of the present invention, an Epothilone is defined as a cyclic molecule with a 16-membered ring and variable substituents and pharmaceutical activity as a cytostatic agent that binds to tubulin (Asnes et al., Anal. Biochem. 1979, 98, 64-73; Job et al., Cellular Pharmacol. 1993, I (Suppl. I), S7-S10; Lichtner et al., PNAS 2001, 98, 11743-11748). The preferred Epothilones for use according to the present invention furthermore show an average distribution coefficient between plasma and brain of 0.3 to 1.5 as measured by the mouse bolus injection assay, as described herein.

A further preferred subgroup is that wherein the Epothilone molecule is a lactone or a lactame molecule.

A preferred subgroup is that wherein the Epothilone shows an average distribution coefficient between plasma and brain of 0.6 to 1.2 in the mouse intravenous bolus injection assay.

A preferred subgroup is the use for the treatment of a brain disease selected from the group consisting of primary brain tumor, secondary brain tumor, Alzheimer’s disease and multiple sclerosis.

Preferred Epothilones for use in the present invention are compounds of the general formula:
wherein:

5 \text{R}^{1a}, \text{R}^{1b} \quad \text{are each independently hydrogen, C}_{1-10} \text{ alkyl, aryl, aralkyl, or together form a} \ -(\text{CH}_2)_m \text{-group where} \ m \ \text{is } 2 \to 5; \\

\text{R}^{2a}, \text{R}^{2b} \quad \text{are each independently hydrogen, C}_{1-10} \text{ alkyl, aryl, aralkyl, or together form a} \ -(\text{CH}_2)_n \text{-group where} \ n \ \text{is } 2 \to 5, \text{ or C}_{2-10} \text{ alkenyl, or C}_{2-10} \text{ alkynyl;}

10 \text{R}^3 \quad \text{is hydrogen, C}_{1-10} \text{ alkyl, aryl, aralkyl;}

\text{R}^{4a}, \text{R}^{4b} \quad \text{are each independently hydrogen, C}_{1-10} \text{ alkyl, aryl, aralkyl, or together form a} \ -(\text{CH}_2)_p \text{-group where} \ p \ \text{is } 2 \to 5; \\

\text{R}^5 \quad \text{is hydrogen, C}_{1-10} \text{ alkyl, aryl, aralkyl, CO}_2\text{H, CO}_2\text{alkyl, CH}_2\text{OH, CH}_2\text{Oalkyl, CH}_2\text{Oacyl, CN, CH}_2\text{NH}_2, \text{ CH}_2\text{N(alkyl, acyl)}_{1,2}, \text{ or CH}_2\text{Hal;}

20
R\textsuperscript{6}, R\textsuperscript{7} are each hydrogen, or together form an additional bond, or together form an epoxy function;

G is O or CH\textsubscript{2};

D-E is a group H\textsubscript{2}C-CH\textsubscript{2}, HC═CH, C═C, CH(OH)-CH(OH), CH(OH)-CH\textsubscript{2},

CH\textsubscript{2}-CH(OH), CH\textsubscript{2}O, O-CH\textsubscript{2}; HC═CH;

W is a group C(=X)R\textsuperscript{8}, or is a bi- or tricyclic aromatic or heteroaromatic radical;

X is O, or two groups OR\textsuperscript{20}, or a C\textsubscript{2}-C\textsubscript{10} alkylenedioxy group (which may be straight or branched), or H/OR\textsuperscript{9}, or a group CR\textsuperscript{10}R\textsuperscript{11};

R\textsuperscript{8} is hydrogen, C\textsubscript{1}-C\textsubscript{10} alkyl, aryl, aralkyl, halogen, CN;

R\textsuperscript{9} is hydrogen or a protecting group PG\textsuperscript{X};

R\textsuperscript{10}, R\textsuperscript{11} are each independently hydrogen, C\textsubscript{1}-C\textsubscript{20} alkyl, aryl, aralkyl, or together with the methylene carbon form a 5- to 7-membered carbocyclic ring;

Z is O or H/OR\textsuperscript{12};

R\textsuperscript{12} is hydrogen or a protecting group PG\textsuperscript{Z};
A-Y is a group O-C(=O), O-CH₂, CH₂-C(=O), NR²¹-C(=O), NR²¹-SO₂;

R²⁰ is a C₁-C₂₀ alkyl group;

R²¹ is hydrogen, or C₁-C₁₀ alkyl;

PG¹, PG² is C₁-C₂₀ alkyl, C₄-C₇ cycloalkyl, which may contain an oxygen atom in the ring, aryl, aralkyl, C₁-C₂₀ acyl, aroyl, C₁-C₂₀ alkylsulfonyl, arylsulfonyl, tri(C₁-C₂₀ alkyl)silyl, di(C₁-C₂₀ alkyl)arylsilyl, (C₁-C₂₀ alkyl)diarylsilyl, or tri(aralkyl)silyl;

as a single stereoisomer or a mixture of different stereoisomers, and / or as a pharmaceutically acceptable salt thereof.

These compounds are advantageously used in the treatment of, or for the manufacture of a medicament for the treatment of, a brain disease associated with proliferative processes.

In a further embodiment, the present invention relates to a method of treating a brain disease associated with proliferative processes comprising administering to an individual in need thereof a therapeutically effective amount of an Epithilone as defined above.

Preferred Embodiments

The term “brain disease associated with proliferative processes” as referred to in the context of the present invention includes, but is not limited to, primary brain tumors such as astrocytomata, oligodendrogliomas, pinealomas, medulloblastomas, neurilemmomatas, meningeomas, and ependymomas, secondary brain tumors, multiple
sclerosis, and Alzheimer’s disease, all of which represent preferred brain diseases associated with proliferative processes to be treated in accordance with the present invention.

5 Particularly preferred brain diseases associated with proliferative processes to be treated by Epothilone administration in accordance with the present invention are primary and secondary brain tumors.

The term “therapeutically effective amount” as used herein refers to that amount of a compound of the invention which, when administered to an individual in need thereof, is sufficient to effect treatment, as defined below, for brain diseases associated with proliferative processes. The amount which constitutes a “therapeutically effective amount” will vary depending on the compound, the disease and its severity, and the age of the human to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.

“Treating” or “treatment” as used herein refers to the treatment of a brain disease in an individual, which disease is associated with proliferative processes; and include:

(i) preventing the disease from recurring in an individual, in particular, when such individual is in need of further medicamentous treatment after a previous surgical or medicamentous therapy;

(ii) inhibiting the disease, i.e., arresting its development; or

(iii) relieving the disease, i.e., causing regression of the disease.

The term “alkyl” as used herein refers to straight or branched alkyl groups, e.g., methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, n-pentyl, neopentyl, heptyl, or decyl. Alkyl groups can be perfluorinated or substituted by one to five substituents selected from the group consisting of halogen, hydroxy, C_1-C_4 alkoxy, or C_5-C_12 aryl (which can be substituted by one to three halogen atoms).
The term "aryl" as used herein refers to an aromatic carbocyclic or heterocyclic moiety containing five to 14 ring atoms, e.g., phenyl, naphthyl, furyl, thienyl, pyridyl, pyrazolyl, pyrimidinyl, oxazolyl, pyridazine, pyrazinyl, chinolyl, or thiazolyl. Aryl groups can be substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkoxy, -CO₂H, -CO₂Alkyl, -NH₂, -NO₂, -N₃, -CN, C₁-C₂₀ alkyl, C₁-C₂₀ acyl, or C₁-C₂₀ acyloxy. The heteroatoms can be oxidized, if this does not cause a loss of aromatic character, e.g., a pyridine moiety can be oxidized to give a pyridine N-oxide.

The term "aralkyl" as used herein refers to a group which can contain up to 14 atoms in the aryl ring (preferred five to ten) and one to eight carbon atoms in the alkyl chain (preferred one to four), e.g., benzyl, phenylethyl, naphthylmethyl, naphthylethyl, furylmethyl, thienylethyl, or pyridylpropyl. The rings can be substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkoxy, -CO₂H, -CO₂Alkyl, -NH₂, -NO₂, -N₃, -CN, C₁-C₂₀ alkyl, C₁-C₂₀ acyl, or C₁-C₂₀ acyloxy.

The protecting groups PG can be alkyl- and/or aryl-substituted silyl moieties, C₁-C₂₀ alkyl, C₄-C₇ cycloalkyl, which may contain an oxygen atom in the ring, aryl, aralkyl, C₁-C₂₀ acyl, aroyl, alkyl- or arylsulfonyl. Groups which can be easily be removed from the molecule are preferred, e.g., methoxymethyl, methoxyethyl, ethoxyethyl, tetrahydropryranyl, tetrahydrofuranyl, trimethylsilyl, triethyisyil, tert-butyldimethylsilyl, tribenzylsilyl, triisopropylsilyl, benzyl, p-nitrobenzyl, p-methoxybenzyl, as well as alkylsulfonyl or arylsulfonyl. Preferred acyl groups are formyl, acetyl, propionyl, pivaloyl, butyryl, or benzoxy, which all can be substituted by one or more amino and/or hydroxy moieties.

A preferred group is compounds of the general formula as given above, wherein A-Y is O-C(=O); D-E is H₂C-CH₂; G is CH₂; Z is O; R₁ᵃ, R₁ᵇ are both C₁-C₁₀ alkyl or form together a -(CH₂)ₚ- group where p is 2 to 3; R₂ᵃ, R₂ᵇ are each independently hydrogen,
C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, or C₂-C₁₀ alkynyl; R³ is hydrogen; R₄ⁿ, R₄ᵇ are each independently hydrogen or C₁-C₁₀ alkyl; R⁵ is C₁-C₁₀ alkyl.

Another preferred group is compounds of the general formula as given above, wherein R²ᵃ, R²ᵇ are each independently hydrogen, C₂-C₁₀ alkenyl or C₂-C₁₀ alkynyl; R⁶, R⁷ form an epoxy function or together form an additional bond; W is a 2-Methylbenzothiazol-5-yl radical or a 2-Methylbenzoxazol-5-yl radical or a Quinoline-7-yl radical.

Of this group, a preferred subgroup is compounds selected from the following:

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1-oxa-9,13-dimethyl-5,5-(1,3-trimethylene)-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-12,16-dimethyl-8,8-(1,3-trimethylene)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl))-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(chinolin-2-yl))-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione; and

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl))-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione.

Another preferred group of compounds has the general formula as given above, wherein R\text{2a}, R\text{2b} are each independently hydrogen, or C_{1}-C_{10} alkyl; R\text{5}, R\text{7} form an epoxy function, or form an additional bond; W is a group C(=X)R\text{8}; X is a group CR^{10}R^{11}; R\text{8} is hydrogen, halogen, C_{1}-C_{10} alkyl; R\text{10}, R\text{11} are hydrogen/2-methylthiazol-4-yl or hydrogen/2-pyridyl.

Of this group, a preferred subgroup is compounds selected from the following:
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-ethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-propyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-propyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,7,9,13-pentamethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-10-ethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylen)-7,9,13-trimethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylen)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylen)-9,13-dimethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylen)-12,16-dimethyl-10-ethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,7,9,13-pentamethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-10-ethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-propyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-10-propyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-propyl-cyclohexadec-13-ene-2,6-dione;


(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5-(1,3-trimethyl)-9,13-dimethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-ethyl-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethyl)-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5-(1,3-trimethyl)-7,9,13-trimethyl-cyclohexadec-13-ene-2,6-dione;
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylen)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-propyl-cyclohexadec-13-ene-2,6-dione;


(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylen)-7,9,13-trimethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylen)-10,12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-10-ethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

and

Another preferred group is compounds of the general formula as given above, wherein \( R^a, R^b \) are each independently hydrogen, \( C_2-C_{10} \) alkenyl or \( C_2-C_{10} \) alkynyl; \( R^8, R^7 \) form an epoxy function or together form an additional bond; \( W \) is a group \( C(=X)R^8; X \) is a group \( CR^{10}R^{11}; R^8 \) is hydrogen, halogen, \( C_1-C_{10} \) alkyl; \( R^{10}, R^{11} \) are hydrogen/2-methylthiazol-4-yl or hydrogen/2-pyridyl.

Of this group, a preferred subgroup is compounds selected from the following:

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-ene-2,6-dione;


(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;


(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-ene-2,6-dione;
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(but-3-in-1-yi)-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(but-3-en-1-yl)-3-(2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)cyclohexadec-13-ene-2,6-dione; and

The synthesis of the compounds listed above is described in the international patent applications WO 99/07692, WO 00/49021, and WO 00/66589, which are incorporated herein by reference.

For the use according to the invention, the compounds can be formulated by methods known in the art. Compositions for the oral, rectal, parenteral or local application can be prepared in the form of tablets, capsules, granulates, suppositories, implantates, sterile injectable aqueous or oily solutions, suspensions or emulsions, aerosols, salves, creams, or gels, retard preparations or retard implantates. The compounds may also be administered by implantable dosing systems.

The pharmaceutical active compound(s) can thus be mixed with adjuvants known in the art, such as gum arabic, talcum, starch, mannitol, methyl cellulose, lactose, surfactants such as tweens® or myrij®, magnesium stearate, aqueous or non-aqueous carriers, paraffin derivatives, wetting agents, dispersing agents, emulsifiers, preservatives, and flavors.

The compounds can be used in the form of their clathrates of α-, β-, or γ-cyclodextrin or of substituted α-, β-, or γ-cyclodextrines, or in the form of a liposomal composition, in particular a liposomal composition comprising a polyethyleneglycol(PEG)-derivatized lipid.

The invention also relates to pharmaceutical compositions containing one or more of the pharmaceutically active compounds listed above, and their use for the treatment and in the methods in accordance with the present invention. Preferably, one dose unit of these compositions contains about 0.01-100 mg of the pharmaceutically active compound(s). The dosage for the use according to the invention for a human is about 0.01-100 mg per day; a preferred dosage is about 0.02-70 mg per day; a more preferred dosage is about 0.04-40 mg per day.
Brief Description of the Figures

Figure 1 shows the plasma and brain concentrations of 4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-thiazolyl)-ethenyl)-1-oxa-7-(1-propyl)-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione (compound 1) after iv application, monitored over a period of 40 min, determined in the animal model of Example 1.

Figure 2 shows the plasma and brain concentrations of $^3$H-labeled dihydroxy-3-(1-methyl-2-(2-methyl-4-thiazolyl)-ethenyl)-10-propyl-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (compound 2) after iv application, monitored over a period of 40 min, determined in the animal model of Example 1.

Figure 3 shows the plasma and brain concentrations of $^3$H-labeled 7,11-dihydroxy-3-(2-methylbenzothiazol-5-yl)-10-(prop-2-en-1-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (compound 3) after iv application, monitored over a period of 40 min, determined in the animal model of Example 1.

Figure 4 shows the plasma and brain concentrations of $^3$H-labeled paclitaxel after iv application, monitored over a period of 40 min, determined in the animal model of Example 1.

Figure 5 shows the brain-plasma-ratio after iv application of the Epothilones of figures 1-3 and paclitaxel as comparison, monitored over a period of 40 minutes, derived from the data of figures 1-4.

Figure 6 shows the evaluation of s.c. tumor growth inhibition by treatment with 7,11-dihydroxy-3-(2-methylbenzothiazol-5-yl)-10-(prop-2-en-1-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione based on tumor volume during the
study of Example 2. The changes of the tumor volume in correlation with the time is shown for the control group A (♦) and the treatment groups B (■) and C (▲).

Figure 7 shows the evaluation of the animal body weight by treatment with 7,11-dihydroxy-3-(2-methylbenzothiazol-5-yl)-10-(prop-2-en-1-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione during the study of Example 2. The changes of the body weight in correlation with the time is shown shown for the control group A (♦) and the treatment groups B (■) and C (▲).

Example 1 (Mouse bolus injection assay)
(In vivo assay for the evaluation of blood and brain levels of Epothilones)

Male SCID mice (20-25 g, non-leaky) were treated with a single dose of tritium-labeled Epothilones and paclitaxel (5 mg/kg; 7.4 MBq/mg; in 30 % Hydroxypropyl-β-cyclodextrin (HPβCD)/NaCl iv bolus injection). Partitioning of radioactivity between blood and brain was measured by liquid scintillation counting (LSC) and HPLC-radioflow at three time points (10, 20 and 40 min) after injection.

The following compounds were tested in this assay:

Paclitaxel;
compound 1: 4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-thiazolyl)-ethenyl)-1-oxa-7-(1-propyl)-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione;
compound 2: dihydroxy-3-(1-methyl-2-(2-methyl-4-thiazolyl)-ethenyl)-10-propyl-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione; and

Results:
All Epothilones were found in the brain at 40 min after iv application in concentrations that exceeded the plasma concentration. For compound 1 and 2 a higher brain plasma ratio was already observed after 20 min. For compound 3 at 10 and 20 minutes a high variation between the animals within one group was observed. 40 minutes after application paclitaxel was detected in the brain in considerable amounts, too.

When comparing the partial (0-40 min) areas under the plasma/brain level time curve, a ratio AUCbrain/AUCplasma of approx. 1 was found (compound 1: 1.0; compound 2: 1.2; compound 3: 0.8) indicating a free access to the brain.

Paclitaxel was below the limit of quantitation in all brain samples but in comparable concentrations in plasma leading to a AUCbrain/AUCplasma ratio of zero.

Concentrations measured for these compounds and AUC ratios calculated thereof are summarized in table 1.

**Conclusion:**

In contrast to paclitaxel, Epothilones seem to penetrate the blood-brain-barrier to a significant extend. Persistance in the brain is longer compared to plasma.
Table 1:

<table>
<thead>
<tr>
<th>Compound (3H-labeled)</th>
<th>Time (min)</th>
<th>Plasma conc. mean, (µg/ml)</th>
<th>Plasma (µg*min/ml) AUC (0-40min)</th>
<th>Brain conc. mean, (µg/g) AUC (0-40min)</th>
<th>Brain (µg*min/ml) AUC (0-40min)</th>
<th>AUC Ratio Brain/Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound 1</td>
<td>10</td>
<td>0.8</td>
<td>20</td>
<td>0.3</td>
<td>21</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>0.6</td>
<td></td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>0.3</td>
<td></td>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compound 2</td>
<td>10</td>
<td>1.6</td>
<td>31</td>
<td>1.1</td>
<td>35</td>
<td>1.2</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>0.7</td>
<td></td>
<td>1.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>0.3</td>
<td></td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compound 3</td>
<td>10</td>
<td>1.2</td>
<td>25</td>
<td>0.9</td>
<td>20</td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>0.7</td>
<td></td>
<td>0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>0.3</td>
<td></td>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>10</td>
<td>0.8</td>
<td>19</td>
<td>&lt;LOQ</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>0.6</td>
<td></td>
<td>&lt;LOQ</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>0.2</td>
<td></td>
<td>&lt;LOQ</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LOQ: Limit of Quantitation
Example 2 (In vivo activity)

In vivo assay for the evaluation of efficacy of Epothilones against xenografted and intracerebral human glioma.

Female NMRI nu/nu-mice (20-28 g) were used for this experiment. Human U373 glioma cells were implanted s.c. (1x10^7/mouse) as well as i.cer. (2x10^5/mouse) on day 0. Treatment was started on day 7 when the s.c. tumors were approximately 0,05 cm³ in size. Treatment was continued until tumor growth in the untreated control group had reached approximately 0,6 cm³ in size on day 32. After termination of the experiment, the size of the brain tumors was determined (Table 2).

The following compounds were tested in this assay:


Results:

A significant therapeutic effect on s.c. (Figure 6) as well as on i.cer. U373 brain tumors is observed for compound 3 for both schedules used in comparison to the rapid growth in the untreated control (Table 2: group B vs. A and group C vs. A).

Only a moderate body weight loss (not significant) is observed in treatment groups B and C (Figure 7).

In treatment group B, 8 from 9 mice show complete remissions of the i. cer. brain tumors.

Conclusion:

From this study it can be concluded that epothilones e.g. compound 3 demonstrated remarkable antitumor efficacy in the U373 brain tumor model.

The response of the s.c. as well as i.cer. U373 model to the treatment with compound 3 is significant in comparison to the untreated control group.

Thus, epothilones, e.g. compound 3, offer the unique potential to be effective for the treatment of brain tumors also in humans.
### Table 2

<table>
<thead>
<tr>
<th>Group</th>
<th>Mice</th>
<th>Substance; Dose i.v. [mg/kg]/appl.</th>
<th>Schedule (days)</th>
<th>Deaths / total (d)</th>
<th>BWC d 7-17 [%]</th>
<th>RTV s.c. Tumor d 25</th>
<th>i. cer. Brain Tumor Volume d 32 [mm³]</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>10</td>
<td>Solvent</td>
<td>7, 9, 11, 14, 16, 18</td>
<td>0/10</td>
<td>4</td>
<td>4.05</td>
<td>43.4</td>
</tr>
<tr>
<td>B</td>
<td>10</td>
<td>Compound 3; 9</td>
<td>7, 14</td>
<td>0/10</td>
<td>-7</td>
<td>1.15</td>
<td>0.002*</td>
</tr>
<tr>
<td>C</td>
<td>10</td>
<td>Compound 3; 2</td>
<td>7, 9, 11, 14, 16, 18</td>
<td>1/10 (21)</td>
<td>-3</td>
<td>1.40</td>
<td>0.96</td>
</tr>
</tbody>
</table>

BWC: Body Weight Change; RTV: Relative Tumor Volume

*: Evaluation of one animal not possible due to incorrect implantation of i.cer. tumor.
Claims

What is claimed is:

1. Use of an Epothilone, which shows an average distribution coefficient between plasma and brain of 0.3 to 1.5 in the mouse intravenous bolus injection assay, for the preparation of a medicament for the treatment of a brain disease associated with proliferative processes.

2. The use of claim 1, wherein the Epothilone is a lactone or a lactame molecule.

3. The use of claim 2, wherein the average distribution coefficient between plasma and brain is 0.6 to 1.2.

4. Use of a compound of the general formula:
wherein

\[ R^{1a}, R^{1b} \] are each independently hydrogen, C\textsubscript{1}-C\textsubscript{10} alkyl, aryl, aralkyl, or together form a \(-(CH_2)_m\)-group where \( m \) is 2 to 5;

\[ R^{2a}, R^{2b} \] are each independently hydrogen, C\textsubscript{1}-C\textsubscript{10} alkyl, aryl, aralkyl, or together form a \(-(CH_2)_n\)-group where \( n \) is 2 to 5, or C\textsubscript{2}-C\textsubscript{10} alkenyl, or C\textsubscript{2}-C\textsubscript{10} alkynyl;

\[ R^3 \] is hydrogen, C\textsubscript{1}-C\textsubscript{10} alkyl, aryl, aralkyl;

\[ R^{4a}, R^{4b} \] are each independently hydrogen, C\textsubscript{1}-C\textsubscript{10} alkyl, aryl, aralkyl, or together form a \(-(CH_2)_p\)-group where \( p \) is 2 to 5;

\[ R^5 \] is hydrogen, C\textsubscript{1}-C\textsubscript{10} alkyl, aryl, aralkyl, CO\textsubscript{2}H, CO\textsubscript{2}alkyl, CH\textsubscript{2}OH, CH\textsubscript{2}Oalkyl, CH\textsubscript{2}Oacyl, CN, CH\textsubscript{2}NH\textsubscript{2}, CH\textsubscript{2}N(alkyl, acyl)\textsubscript{1,2}, or CH\textsubscript{2}Hal;

\[ R^6, R^7 \] are each hydrogen, or together form an additional bond, or together form an epoxy function;

\[ G \] is O or CH\textsubscript{2};

\[ D-E \] is a group H\textsubscript{2}C-CH\textsubscript{2}, HC=CH, C≡C, CH(OH)-CH(OH), CH(OH)-CH\textsubscript{2},

\[
\begin{array}{c}
\text{O} \\
\text{CH}_2\text{-CH(OH)}, \text{CH}_2\text{-O, O-CH}_2; \text{or HC—CH;} \\
\end{array}
\]
W is a group C(=X)R^8, or is a bi- or tricyclic aromatic or heteroaromatic radical;

X is O, or two groups OR^{20}, or a C_2-C_{10} alkylenedioxy group (which may be straight or branched), or H/OR^9, or a group CR^{10}R^{11};

R^8 is hydrogen, C_1-C_{10} alkyl, aryl, aralkyl, halogen, CN;

R^9 is hydrogen or a protecting group PG^X;

R^{10}, R^{11} are each independently hydrogen, C_1-C_{20} alkyl, aryl, aralkyl, or together with the methylene carbon form a 5- to 7-membered carbocyclic ring;

Z is O or H/OR^{12};

R^{12} is hydrogen or a protecting group PG^Z;

A-Y is a group O-C(=O), O-CH_2, CH_2-C(=O), NR^{21}-C(=O), or NR^{21}-SO_2;

R^{20} is a C_1-C_{20} alkyl group;

R^{21} is hydrogen, or C_1-C_{10} alkyl;

PG^X, PG^Z is C_1-C_{20} alkyl, C_4-C_7 cycloalkyl, which may contain an oxygen atom in the ring, aryl, aralkyl, C_1-C_{20} acyl, aroyl, C_1-C_{20} alkylsulfonyl, arylsulfonyl, tri(C_1-C_{20} alkyl)silyl, di(C_1-C_{20} alkyl) arylsilyl, (C_1-C_{20} alkyl) diarylsilyl, or tri(aryl)silyl;
as a single stereoisomer or a mixture of different stereoisomers,
and / or as a pharmaceutically acceptable salt thereof,

5

for the preparation of a medicament for the treatment of a brain disease
associated with proliferative processes.

5. The use of any one of claims 1-4, where the brain disease is selected from the
group consisting of primary brain tumor, secondary brain tumor, Alzheimer's
disease and multiple sclerosis.

15 6. The use of any one of claims 4 or 5, wherein

A-Y is O-C(=O);

D-E is H₂C-CH₂;

G is CH₃;

Z is O;

25 R¹a, R¹b are both C₁-C₁₀ alkyl or together form a –(CH₂)ₘ group where m
is 2 or 3;

R²a, R²b are each independently hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, or
C₂-C₁₀ alkynyl;
\[ R^3 \text{ is hydrogen;} \]
\[ R^{4a}, R^{4b} \text{ are each independently hydrogen or } C_1-C_{10} \text{ alkyl;} \]
\[ R^5 \text{ is } C_1-C_{10} \text{ alkyl.} \]

7. The use of any one of claims 4-6, wherein
\[ R^{2a}, R^{2b} \text{ are each independently hydrogen, } C_2-C_{10} \text{ alkenyl or } C_2-C_{10} \text{ alkynyl;} \]
\[ R^6, R^7 \text{ together form an epoxy function or an additional bond; and} \]
\[ W \text{ is a 2-Methylbenzothiazol-5-yl radical, a 2-Methylbenzoxazol-5-yl radical, or a Quinoline-7-yl radical.} \]

8. The use of claim 7, wherein the compound is selected from the group consisting of:
\[ (4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione; \]
\[ (1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione; \]
\[ (4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione; \]
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1-oxa-9,13-dimethyl-5,5-(1,3-trimethylene)-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-12,16-dimethyl-8,8-(1,3-trimethylene)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;

and
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione.

9. The use of any one of claims 4-6, wherein

\[ R^{2a}, R^{2b} \]

are each independently hydrogen, or C\(_1\)-C\(_{10}\) alkyl;

\[ R^6, R^7 \]

together form an epoxy function or an additional bond;

\[ W \]

is a group C(=X)R\(^8\);

\[ X \]

is a group CR\(^{10}\)R\(^{11}\);

\[ R^8 \]

is hydrogen, halogen, or C\(_1\)-C\(_{10}\) alkyl; and

\[ R^{10}, R^{11} \]

are hydrogen/2-methylthiazol-4-yl or hydrogen/2-pyridyl.

10. The use of claim 9, wherein the compound is selected from the group consisting of:

\( (4S,7R,8S,9S,13E/Z,16S(E))-4,8\)-dihydroxy-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

\( (1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11\)-dihydroxy-10-ethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-
thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylene)-9,13-dimethyl-7-ethyl-
cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-ethyl-3-(1-methyl-2-
(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylene)-12,16-dimethyl-4,17-
dioxabicyclo[14.1.0]heptadecan-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-
thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-propyl-cyclohexadec-13-ene-
2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-propyl-3-(1-methyl-2-
(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-4,17-
dioxabicyclo[14.1.0]heptadecan-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-
thiazolyl)ethenyl)-1-oxa-5,5,7,9,13-pentamethyl-cyclohexadec-13-ene-2,6-
dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-
thiazolyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-
dioxabicyclo[14.1.0]heptadecan-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-
thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-
dione;
(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-10-ethyl-4,17-
dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethyl)-7,9,13-trimethyl-cyclohexadec-
en-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethyl)-10,12,16-trimethyl-4,17-
dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethyl)-9,13-dimethyl-7-ethyl-
cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethyl)-12,16-dimethyl-10-ethyl-4,17-
dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,7,9,13-pentamethyl-cyclohexadec-13-ene-2,6-
dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-
dioxabicyclo[14.1.0]heptadecane-5,9-dione;
(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-10-ethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-propyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-10-propyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-propyl-cyclohexadec-13-ene-2,6-dione;


(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5-(1,3-trimethylen)-9,13-dimethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-ethyl-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylen)-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5-(1,3-trimethylen)-7,9,13-trimethyl-cyclohexadec-13-ene-2,6-dione;

(1S,R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylen)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-propyl-cyclohexadec-13-ene-2,6-dione;


(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylen)-7,9,13-trimethyl-cyclohexadec-13-ene-2,6-dione;

(1S,R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylen)-10,12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione;

(1S,R,3S(Z),7S,10R,11S,12S,16R/S)-7,11-dihydroxy-3-(1-chlor-2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-10-ethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-ethyl-cyclohexadec-13-ene-2,6-dione; and


11. The use of any one of claims 4-6, wherein

\[ R^{2a}, R^{2b} \] are each independently hydrogen, C\(_2\)-C\(_{10}\) alkenyl or C\(_2\)-C\(_{10}\) alkynyl;

\[ R^6, R^7 \] together form an epoxy function or an additional bond;

\[ W \] is a group C(=X)R\(^8\);

\[ X \] is a group CR\(^{10}\)R\(^{11}\);

\[ R^8 \] is hydrogen, halogen, or C\(_1\)-C\(_{10}\) alkyl; and

\[ R^{10}, R^{11} \] are hydrogen/2-methylthiazol-4-yl or hydrogen/2-pyridyl.

12. The use of claim 11, wherein the compound is selected from the group consisting of:

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-ene-2,6-dione;

(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione;


(4S,7R,8S,9S,13E/Z,16S(E))-4,8-dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-ene-2,6-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(but-3-en-1-yl)-3-(2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-ene-2,6-dione;
(1S/R,3S(Z),7S,10R,11R,12S,16R/S)-7,11-dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

(4S,7R,8S,9S,13E/Z,16S(Z))-4,8-dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-ene-2,6-dione; and


13. A method of treating a brain disease associated with proliferative processes comprising administering to an individual in need thereof a therapeutically effective amount of an Epothilone as defined in any one of claims 1 to 12.

14. The use or the method according to any one of claims 1 to 12, wherein the medicament or the Epothilone is to be administered orally, parenterally, rectally, or locally.
Fig 1:

**Compound 1**
Plasma and Brain Concentration after iv Application

- • Compound 1-Plasma
- ○ Compounds 1-Brain

Concentration (µg/ml)

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2.0</td>
<td>1.5</td>
<td>1.0</td>
<td>0.5</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>1.5</td>
<td>1.0</td>
<td>0.5</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>1.0</td>
<td>0.5</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>0.5</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Compound 1: 4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-thiazolyl)-ethenyl)-1-oxa-7-(1-propyl)-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione

Fig 2:

**Compound 2**
Plasma and Brain Concentration after iv Application

- • Compound 2-Plasma
- ◦ Compound 2-Brain

Concentration (µg/ml)

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2.0</td>
<td>1.5</td>
<td>1.0</td>
<td>0.5</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>1.5</td>
<td>1.0</td>
<td>0.5</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>1.0</td>
<td>0.5</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>0.5</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Compound 2: dihydroxy-3-(1-methyl-2-(2-methyl-4-thiazolyl)-ethenyl)-10-propyl-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
Fig. 3:

**Compound 3**

Plasma and Brain Concentration after iv Application

![Graph](image)

Compound 3: 7,11-dihydroxy-3-(2-methylbenzothiazol-5-yl)-10-(prop-2-en-1-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

Fig. 4:

**Paclitaxel**

Plasma and Brain Concentration after iv Application

![Graph](image)

Compound: Paclitaxel
5 Compound 1: 4,8-dihydroxy-16-(1-methyl-2-(2-methyl-4-thiazoly1)-ethenyl)-1-oxa-7-(1-propyl)-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione;

Compound 2: dihydroxy-3-(1-methyl-2-(2-methyl-4-thiazoly1)-ethenyl)-10-propyl-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
A61P25/28. - A61P35/00 -

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, MEDLINE, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 01 92255 A (KOSAN BIOSCIENCES INC ;ASHLEY GARY (US); FARDIS MARIA (US); SANTI) 6 December 2001 (2001-12-06) page 39, line 18-20 page 41, line 7 claims 17,18,21,22</td>
<td>1-7,9, 13,14</td>
</tr>
<tr>
<td>Y</td>
<td>WO 99 67253 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); NICOLAOU KYRIACOS) 29 December 1999 (1999-12-29) page 3, paragraph 2 claims 1-8</td>
<td>1-14</td>
</tr>
<tr>
<td>X</td>
<td></td>
<td>1-6,9, 13,14</td>
</tr>
<tr>
<td>Y</td>
<td></td>
<td>1-14</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

<table>
<thead>
<tr>
<th>Category</th>
<th>citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

FURTHER DOCUMENTS

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier document published on or after the International filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an earlier disclosure, use, exhibition or other means
  "P" document published prior to the International filing date but later than the priority date claimed

"T" Patent family members are listed in annex.

Date of the actual completion of the international search
21 May 2003

Date of mailing of the international search report
28/05/2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer
Bazzanini, R

Form PCT/ISA/210 (second sheet) (July 1993)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 99 02514 A (SQUIBB BRISTOL MYERS CO) 21 January 1999 (1999-01-21) cited in the application page 9, line 5-6 page 9, line 21 - page 10, line 9 claims 1,2,4</td>
<td>1-6,9, 13,14</td>
</tr>
<tr>
<td>Y</td>
<td>---</td>
<td>1-14</td>
</tr>
<tr>
<td>X</td>
<td>WO 99 62510 A (ANGIOTECH PHARM INC ; HUNTER WILLIAM L (CA)) 9 December 1999 (1999-12-09) claims 1,2,6,9,12</td>
<td>1-6,9, 13,14</td>
</tr>
<tr>
<td>Y</td>
<td>---</td>
<td>1-14</td>
</tr>
<tr>
<td>X</td>
<td>WO 01 24763 A (IMMUNOGEN INC ; CHARI RAVI V J (US)) 12 April 2001 (2001-04-12) claims 1,2,18-20,31,32</td>
<td>1-6,9, 13,14</td>
</tr>
<tr>
<td>Y</td>
<td>---</td>
<td>1-14</td>
</tr>
<tr>
<td>X</td>
<td>LARNER A.J.: &quot;Neuronal apoptosis as a therapeutic target in neurodegenerative disease.&quot; EXPERT OPINION ON THERAPEUTIC PATENTS, (2000) 10/10 (1493-1518)., XP000109764 page 1508, left-hand column, line 2-10 * page 1508, formula 47, 48 *</td>
<td>1-6,13, 14</td>
</tr>
<tr>
<td>Y</td>
<td>---</td>
<td>1-14</td>
</tr>
<tr>
<td>Y</td>
<td>WO 00 66589 A (HOFFMANN JENS ; KLAR ULRICH (DE); BUCHMANN BERND (DE); SKUBALLA WER) 9 November 2000 (2000-11-09) cited in the application page 219, line 1-8 claims 1-21 page 246, line 20-22</td>
<td>1-6,9, 13,14</td>
</tr>
<tr>
<td>Y</td>
<td>WO 99 07692 A (KLAR ULRICH ; SCHERING AG (DE); BUCHMANN BERND (DE); SKUBALLA WERNE) 18 February 1999 (1999-02-18) cited in the application claims 1-8 page 165, line 6-11</td>
<td>1-6,9, 13,14</td>
</tr>
<tr>
<td>Y</td>
<td>WO 00 49021 A (KLAR ULRICH ; SCHERING AG (DE); BUCHMANN BERND (DE); SKUBALLA WERNE) 24 August 2000 (2000-08-24) cited in the application claims 1-55 page 94, line 13-20</td>
<td>1-6,9, 13,14</td>
</tr>
</tbody>
</table>

Form PCT/ISA2610 (continuation of second sheet) (July 1999)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
| Y        | NICOLAOU K C ET AL: "Chemical Biology of Epothilones"  
ANGEWANDTE CHEMIE. INTERNATIONAL EDITION,  
VERLAG CHEMIE. WEINHEIM, DE,  
vol. 37, no. 15, August 1998 (1998-08),  
pages 2014-2045, XP002131418  
ISSN: 0570-0833  
page 2037, left-hand column, paragraph 2  
–page 2040, right-hand column, paragraph 3  
tables 1-6  
figure 10 | 1-14 |
INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. X Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:
   Although claims 13 and 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. X Claims Nos.:
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
   see FURTHER INFORMATION sheet PCT/ISA/210

3.☐ Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2.☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4.☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest
☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.
Continuation of Box I.2

Present claims 1-6,7,9,11 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims lack support, and the application lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Moreover, present claims 1-14 relate to a compound defined (inter alia) by reference to the following parameter: "average distribution coefficient between plasma and brain". The use of this parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameter the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible.

Also, independent of the above reasoning, an attempt is made to define the compound by reference to its pharmacological profile (i.e. pharmacokinetics), rendering the scope of protection of said claims obscure (Art 6 PCT). It is pointed out that a compound cannot be sufficiently characterized by its pharmacokinetics. The use of such a functional definition is vague and unclear and leaves the reader in doubt as to the meaning of the technical feature (e.g. compounds) to which it refers.

Furthermore, it could be understood that all the compounds falling under formulae of claims 4,6-12 possess the claimed "average distribution coefficient between plasma and brain", which seems to be essential for the treatment of the claimed brain diseases.

Consequently, the search concerning the compounds has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds listed in claims 8,10 and 12.

However some of the compounds listed in claim 8 (i.e. all the compounds of the series "dioxabicyclo") don't seem to correspond to the definition of substituent W given in claim 7 (see "(1-methyl-2" moiety before heterocyclic radical of "dioxabicyclo" compounds of claim 8). Therefore for the "dioxabicyclo" compounds the search has been performed taking into account the substituent W as described in claim 7.

Furthermore, present claims 1-4 relate to the treatment of a disease which actually is not well defined. The use of the definition "brain disease associated with proliferative process" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to determine the diseases for which protection might legitimately be sought. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search concerning the therapeutic application of the claimed compounds has been restricted to the diseases listed in claim 5 and those reported in the description from page 8, line 27 to page 9, line 3.
Claims searched incompletely: 1-14
Claims searched completely: none

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.
<table>
<thead>
<tr>
<th>Patent document</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 0192255</td>
<td>06-12-2001</td>
<td>AU 6658301 A</td>
<td>11-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0192255 A2</td>
<td>06-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2002045609 A1</td>
<td>18-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 757854 B2</td>
<td>06-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4774899 A</td>
<td>10-01-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4775299 A</td>
<td>10-01-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9911420 A</td>
<td>20-03-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2334342 A1</td>
<td>29-12-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1306531 T</td>
<td>01-08-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9967252 A2</td>
<td>29-12-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9967253 A2</td>
<td>29-12-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1089998 A2</td>
<td>11-04-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0102711 A2</td>
<td>28-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002518504 T</td>
<td>25-06-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20006378 A</td>
<td>21-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 345327 A1</td>
<td>17-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 19712000 A3</td>
<td>11-09-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TR 200003844 T2</td>
<td>20-04-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6531497 B1</td>
<td>11-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7972098 A</td>
<td>08-02-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 104068 A</td>
<td>29-09-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9810555 A</td>
<td>15-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1270589 T</td>
<td>18-10-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EE 200000013 A</td>
<td>15-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1019389 A2</td>
<td>19-07-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0103111 A2</td>
<td>29-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002512634 T</td>
<td>23-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LT 99153 A,B</td>
<td>25-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LV 12569 A</td>
<td>20-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LV 12569 B</td>
<td>20-04-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20000076 A</td>
<td>07-01-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 501198 A</td>
<td>28-09-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 338003 A1</td>
<td>25-09-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 181799 A3</td>
<td>06-08-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TR 200000065 T2</td>
<td>21-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9902514 A2</td>
<td>21-01-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9805938 A</td>
<td>10-01-2000</td>
</tr>
<tr>
<td>WO 9962510</td>
<td>09-12-1999</td>
<td>US 6495679 B1</td>
<td>17-12-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4025599 A</td>
<td>20-12-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9962510 A2</td>
<td>09-12-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2002183380 A1</td>
<td>05-12-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2002013298 A1</td>
<td>31-01-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2385528 A1</td>
<td>12-04-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1229934 A2</td>
<td>14-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0124763 A2</td>
<td>12-04-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 10015836 A1</td>
<td>11-10-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 19954228 A1</td>
<td>13-09-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4310300 A</td>
<td>17-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 106053 A</td>
<td>31-05-2002</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
<td>Publication date</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>WO 0066589</td>
<td></td>
<td>BR 0010190 A</td>
<td>08-01-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2371226 A1</td>
<td>09-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1349534 T</td>
<td>15-05-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 20013885 A3</td>
<td>17-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EE 200100568 A</td>
<td>17-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0201010 A2</td>
<td>28-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0066589 A1</td>
<td>09-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002543203 T</td>
<td>17-12-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20015278 A</td>
<td>21-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 15512001 A3</td>
<td>09-05-2002</td>
</tr>
</tbody>
</table>

|                                       |                 | DE 19735575 A1         | 11-02-1999      |
|                                       |                 | DE 19735578 A1         | 11-02-1999      |
|                                       |                 | DE 19748928 A1         | 29-04-1999      |
|                                       |                 | DE 19749717 A1         | 06-05-1999      |
|                                       |                 | DE 19751200 A1         | 20-05-1999      |
|                                       |                 | DE 19813821 A1         | 23-09-1999      |
|                                       |                 | AU 9340998 A           | 01-03-1999      |
|                                       |                 | WO 9907692 A2          | 18-02-1999      |
|                                       |                 | EP 1005465 A2          | 07-06-2000      |
|                                       |                 | JP 2001512723 T        | 28-08-2001      |
|                                       |                 | ZA 9810403 A           | 15-05-2000      |

| WO 0049021                            | 24-08-2000      | DE 19908765 A1         | 24-08-2000      |
|                                       |                 | DE 19954230 A1         | 15-11-2001      |
|                                       |                 | AU 3156700 A           | 04-09-2000      |
|                                       |                 | BG 105802 A            | 29-03-2002      |
|                                       |                 | BR 0008331 A           | 29-01-2002      |
|                                       |                 | CA 2361278 A1          | 24-08-2000      |
|                                       |                 | CN 1341115 T           | 20-03-2002      |
|                                       |                 | CZ 20012951 A3         | 14-11-2001      |
|                                       |                 | EE 200100431 A         | 16-12-2002      |
|                                       |                 | WO 0049021 A2          | 24-08-2000      |
|                                       |                 | EP 1150980 A2          | 07-11-2001      |
|                                       |                 | HU 0105478 A2          | 29-06-2002      |
|                                       |                 | JP 2002537301 T        | 05-11-2002      |
|                                       |                 | NO 20014013 A          | 18-10-2001      |
|                                       |                 | PL 349863 A1           | 23-09-2002      |
|                                       |                 | SK 11852001 A3         | 04-04-2002      |